Clinical Trial Update: Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating valganciclovir therapy in infants and children with congenital cytomegalovirus infection and hearing loss has completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Cytomegalovirus Infection
• Cytomegalovirus Infection

Drugs mentioned

• Valcyte (valganciclovir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cytomegalovirus Infection | Phase 2 | Status: COMPLETED | Results posted: 2021-06-02